Business Context and Reporting Period
Company: Aytu BioScience, Inc. (AYTU)
Filing Type: Form 8-K (Current Report)
Date of Report: September 12, 2019
Event: Entry into a Material Definitive Agreement (Merger Agreement) with Innovus Pharmaceuticals, Inc. ("Innovus"). Aytu Acquisition Sub, Inc., a wholly-owned subsidiary of Aytu, will merge with and into Innovus, with Innovus surviving as a wholly-owned subsidiary of Aytu.
Key Financial Metrics and Transaction Terms
Consideration Structure: Innovus shareholders will receive:
- Shares of Aytu common stock.
- Cash in lieu of fractional shares.
- One non-transferrable Contingent Value Right (CVR) per share.
Contingent Value Rights (CVRs): CVRs entitle holders to additional payments (cash or stock) if Innovus's "Consumer Business Unit" meets specific revenue and profitability milestones from 2019 to 2023. Potential aggregate payments include:
- 2019: $2,000,000 if revenue reaches $24 million.
- 2020: Up to $2,000,000 ($1M for $30M revenue; $1M for break-even profitability).
- 2021: Up to $2,000,000 ($1M for $40M revenue; $1M for profitability).
- 2022: Up to $5,000,000 ($2.5M for $50M revenue; $2.5M for profitability).
- 2023: Up to $5,000,000 ($2.5M for $75M revenue; $2.5M for profitability).
Termination Fees: $250,000 payable by either party under specific termination scenarios (e.g., failure to obtain shareholder approval, breach of representations, or superior proposal).
Financial Data: The filing text does not provide current revenue, profit, cash flow, margins, debt, or liquidity figures for Aytu or Innovus.
Material Changes and Conditions
Closing Conditions: The merger is subject to customary conditions, including:
- Adoption of the Merger Agreement by a majority of Innovus stockholders.
- Approval of the equity issuance by a majority of Aytu stockholders.
- Nasdaq listing approval for Aytu stock to be issued.
- Effectiveness of the SEC registration statement.
- Entry into the CVR Agreement.
- Execution of employment or separation agreements for certain officers.
Termination Rights: Either party may terminate if the merger is not completed by May 15, 2020 (subject to extension), if shareholder approvals fail, if a governmental order prohibits the merger, or if a "Superior Proposal" is received by Innovus.
Voting Agreements: Aytu executives and certain stockholders covering approximately 35% of Aytu's voting stock, and 17% of Innovus's voting stock, have agreed to vote in favor of the merger.
Guidance, Risks, and Contingencies
Forward-Looking Statements: The filing contains predictions regarding the transaction's completion, synergies, and future financial performance, which are subject to significant risks.
Key Risks:
- Failure to obtain required shareholder votes.
- Failure to satisfy closing conditions or regulatory approvals.
- Termination of the agreement by either party.
- Failure of Innovus to meet revenue/profitability milestones, resulting in no CVR value.
- Integration challenges and diversion of management time.
- Changes in capital markets affecting financing.
CVR Adjustments: Potential CVR payments may be reduced if Aytu's losses relating to certain Innovus legal matters exceed specific thresholds. Warrant exercises by Innovus prior to the merger will result in the issuance of additional CVRs to those holders.
Investor Verification Checklist
- Verify the final terms of the Merger Agreement and CVR Agreement in the attached exhibits (Exhibit 2.1 and 10.1).
- Review the upcoming Form S-4 Registration Statement and Joint Proxy Statement/Prospectus for detailed financial data and risk factors.
- Confirm the status of shareholder approval votes for both Aytu and Innovus.
- Monitor the performance of Innovus's Consumer Business Unit against the 2019-2023 revenue and profitability milestones.
- Check for any regulatory stop orders or injunctions that could prevent the merger.
- Assess the impact of the $250,000 termination fee provisions on the transaction's stability.